AlphAIAlphAI — Financial news for AI agents
newstribune.comOCT 223 min read$ABT

Abbott Laboratories plans to spin off nutrition business after years of turmoil over infant formulas

Abbott Laboratories (ABT) plans to spin off its nutrition business, including brands like Similac and Pedialyte, by late 2027. The new company will have $8.5B in annual sales and 16,000 employees. Abbott's nutrition sales fell 4.5% in the U.S. in 2026, amid lawsuits and recalls. The spinoff aims to focus resources and benefit both entities, according to the company.

Original reporting
newstribune.com
Published Oct 22, 2026, 9:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Laboratories plans to spin off nutrition business after years of turmoil over infant formulas — source image
Source · newstribune.com
Decision brief

The 30-second read

$ABTNeutralMed
01

Why it matters

The spin‑off aims to isolate the nutrition business, potentially improving focus for both entities while addressing liability concerns.

02

Market read

A major corporate restructuring that could reshape valuation for Abbott and create a new listed nutrition company.

03

What to watch

Regulatory approvals and ongoing litigation risks could delay or diminish the spin‑off's value.

Relevance 7/10Novelty 8/10Timing: announcement today

Background

Abbott has faced years of litigation and recalls related to its infant formula products, prompting a strategic separation.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott announced a plan to spin off its nutrition business into a new $8.5 billion company, distributing shares to existing shareholders.

Expected impact

likely modest downside as the market prices in the separation and allocates value between ABT and the new spin‑off.

Evidence & confidence

Large‑scale corporate action with clear financial details; investors typically adjust pricing on both parent and spin‑off shares on announcement.

Market effects

Sector

Nutrition and infant formula segment may see increased focus; peers could experience relative valuation shifts.

Regional

U.S. healthcare and consumer staples markets may adjust exposure to Abbott's nutrition business.

Global

Potential ripple effects for global suppliers and competitors in the nutrition space.

Counterpoint

What could challenge this read

If the spin‑off fails to achieve operational independence, the market could penalize both entities, presenting a buying opportunity on a dip.

Key entities

  • company
    Abbott Laboratories

    Parent company planning the spin‑off.

  • executive
    Robert Ford

    Chairman and CEO of Abbott, announced the separation.

Read at source← All news

StoryAbbott Laboratories to spin off its nutrition business into a standalone public company

Also covered by

3 outlets

Related articles

OCT 23
$ABTMed

StoneX reiterates Buy on Abbott Labs stock, $120 target unchanged

StoneX reiterated a Buy rating and $120 target for Abbott Labs (ABT) after Q3 results. Abbott lowered its full-year revenue guidance to 6% and adjusted EPS to $5.50-$5.55. StoneX reduced its 2026 and 2027 revenue and EPS estimates. Abbott's Q3 revenue was $13.01B, up 7%, with adjusted EPS of $1.42. The company plans to spin off its Nutrition business by 2027. Analysts have mixed reactions to the guidance changes.

investing.com1 min
OCT 23
$ABTMedAI 8/10

Abbott’s colorectal cancer test shows improved sensitivity

Abbott (NYSE: ABT) presented data at the European Society for Medical Oncology Congress showing its Oncodetect test for colorectal cancer recurrence achieved 72.2% sensitivity, outperforming its previous version. The study analyzed 279 patients, detecting additional cases with the new test. Patients with detectable ctDNA had higher recurrence risk and lower survival rates. The test is not FDA-approved and is performed at Genomic Health Inc.

investing.com2 min
OCT 23
$ABTMedAI 8/10

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Abbott (NYSE: ABT) presented data at ESMO 2026 showing its Oncodetect® test improved sensitivity for detecting colorectal cancer recurrence by 30% compared to its previous test. The study found a 10.6-fold higher recurrence risk for patients with detectable ctDNA. Abbott aims to connect innovations across cancer care, from early detection to post-treatment monitoring.

prnewswire.com2 min
OCT 22
$ABTMed

ABT Maintained by RBC Capital -- Price Target Lowered to $125

RBC Capital maintained an 'Outperform' rating on Abbott Laboratories (ABT) but lowered its price target from $130 to $125. GuruFocus values ABT at $135.74, suggesting a 24.9% undervaluation. The company has a GF Score of 82/100, indicating strong financial health and growth potential, but insiders have sold $46.85M in shares over the past three months.

gurufocus.com2 min